What is she best known for?
The fields of study she is best known for:
Annette Oxenius mainly investigates Immunology, T cell, Cytotoxic T cell, Virology and Immune system.
Her work in CD8, Interleukin 21, Virus, Lymphocytic choriomeningitis and Cytokine is related to Immunology.
As a part of the same scientific family, she mostly works in the field of CD8, focusing on Epitope and, on occasion, Influenza A virus.
Her work deals with themes such as Molecular biology, Interleukin 12 and CD40, which intersect with T cell.
Her Virology research is multidisciplinary, relying on both Cellular immunity, Cytokine secretion and In vivo.
Annette Oxenius has researched Immune system in several fields, including Antibody and Mass cytometry.
Her most cited work include:
- HIV preferentially infects HIV-specific CD4 + T cells (1081 citations)
- Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies (472 citations)
- Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes (357 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Immunology, Cytotoxic T cell, Virology, T cell and CD8.
Immune system, Virus, Interleukin 21, Lymphocytic choriomeningitis and Cytokine are among the areas of Immunology where Annette Oxenius concentrates her study.
Her Cytotoxic T cell research integrates issues from Antigen and Cell biology.
Her Virology research includes themes of Epitope, Antibody and T lymphocyte.
Her T cell research includes elements of Vaccination, Priming and Effector.
Annette Oxenius has included themes like Adoptive cell transfer, Cytokine secretion, Major histocompatibility complex and Immunopathology in her CD8 study.
She most often published in these fields:
- Immunology (60.70%)
- Cytotoxic T cell (44.10%)
- Virology (34.93%)
What were the highlights of her more recent work (between 2018-2021)?
- Immunology (60.70%)
- T cell (30.13%)
- Cytotoxic T cell (44.10%)
In recent papers she was focusing on the following fields of study:
Annette Oxenius focuses on Immunology, T cell, Cytotoxic T cell, Virus and Immune system.
Annette Oxenius usually deals with T cell and limits it to topics linked to Cell biology and Viral replication, Receptor and Spleen.
Her Cytotoxic T cell study combines topics in areas such as Priming, CD8, Antigen and Virology.
She interconnects Cd4 t cell, B-cell activation and Monoclonal in the investigation of issues within Virology.
The Virus study combines topics in areas such as Effector, Antibody, Antibody Repertoire and Lymphocytic choriomeningitis.
Her biological study spans a wide range of topics, including Congenital cytomegalovirus infection, Phenotype, Computational biology and Function.
Between 2018 and 2021, her most popular works were:
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) (345 citations)
- MHC class II proteins mediate cross-species entry of bat influenza viruses (41 citations)
- Modulation of asymmetric cell division as a mechanism to boost CD8+ T cell memory (14 citations)
In her most recent research, the most cited papers focused on:
Her scientific interests lie mostly in Cytotoxic T cell, T cell, Virus, Cell biology and Immunology.
Her research in Cytotoxic T cell intersects with topics in CD8, Antigen and Vaccination.
Annette Oxenius focuses mostly in the field of CD8, narrowing it down to matters related to Chronic infection and, in some cases, Lymphocytic choriomeningitis and Adoptive cell transfer.
Her research brings together the fields of Immune system and Virus.
Her studies in Cell biology integrate themes in fields like Spleen and T-cell receptor.
Her Effector study, which is part of a larger body of work in Immunology, is frequently linked to Context, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
